Amrutanjan Healt (AMRUTANJAN)

FairStock Score: 24/100 — RISKY

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

When I look at Amrutanjan Health, I first note the balance sheet: debt-to-equity of just 0.01. That is the kind of conservatism Graham would admire. The company earns a return on equity of 19.11% and a return on capital of 22.45%, with a Piotroski F-Score of 7/9, indicating decent financial health. Promoters own 46.52%, so their interests are aligned with shareholders. But I cannot ignore the price I am asked to pay. At ₹578, the stock trades at 29.84 times earnings and 5.49 times book value. That is a demanding price for a business whose profit growth is only 5.82%, even if sales are growing at 14.90%. The PEG ratio of 2.88 tells me the market is paying a rich premium for growth that isn't translating to the bottom line. Sales grew nicely, but profits lagged badly — that suggests rising costs, margin pressure, or lower operating leverage. The latest quarter shows ₹141 Cr in sales and ₹19 Cr in net profit, so the business is not collapsing, but the earnings quality is weaker than the sales story. The FairStock Score of 29/100 labels this risky, and I agree. The dividend yield of just 0.77% offers little comfort while waiting for growth. The stock is well off its 52-week high of ₹790.95, but being down from a high does not mean cheap. A wonderful business can be a poor investment at the wrong price. Amrutanjan has a solid franchise and a fortress balance sheet, but at nearly 30 times earnings with single-digit profit growth, I would need a significant margin of safety before investing. Patience, not optimism, must drive the entry price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer